版本:
中国

BRIEF-Mabvax Therapeutics provides interim progress on programs

Sept 19 Mabvax Therapeutics Holdings Inc

* Mabvax therapeutics reports on interim progress on its programs including the phase i clinical trial for therapeutic antibody treatment of pancreatic cancer

* Co intends on providing a more comprehensive interim data analysis upon obtaining sufficient patient data before year-end

* Would initiate phase I trial for MVT-1075 in first half of 2017 after receiving FDA authorization to proceed

* Remain on track for submitting investigational new drug application (IND) for MVT-1075 to FDA later this year Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐